Patients are already clamoring for “the longer acting Botox,” a not-yet approved treatment from Revance Therapeutics, CEO Dan Browne told Bloomberg News.
The launch won’t happen for another two years or so, and while many patients want more time looking younger, doctors are looking for a longer acting product for therapeutic goals.
RT002, as the drug is known, is still in late-stage testing for its first indication — expected to be glabellar lines.
